This article is
- freely available
The Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer
Hedley Atkins Breast Unit, Guy’s Hospital, London SE1 9RT, UK
* Author to whom correspondence should be addressed.
Received: 31 March 2010; in revised form: 26 April 2010 / Accepted: 10 May 2010 / Published: 17 May 2010
Abstract: Epidemiological evidence suggests that non-steroidal anti-inflammatory drugs (NSAIDs) which act as cyclooxygenase (COX-2) inhibitors may reduce breast cancer incidence by up to 20%. These agents are often taken for pain relief by older women with osteoarthritis. Age is the major risk factor for breast cancer in women with 50% cases being diagnosed in those aged >65 years. NSAIDs reduce serum estradiol by 17% in post-menopausal women and since most of these who develop breast cancers have estrogen receptor positive tumours; this suggests a possible preventative role. Careful use of these agents could provide a strategy for both relief of symptoms of osteoarthritis and also breast cancer prevention. Instead of conducting a randomised trial, proof of efficacy could be from an adequately powered cohort study within the breast screening programme.
Keywords: non-steroidal anti-inflammatory drugs; breast cancer; chemoprevention
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Horn, S.L.; Fentiman, I.S. The Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer. Pharmaceuticals 2010, 3, 1550-1560.
Horn SL, Fentiman IS. The Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer. Pharmaceuticals. 2010; 3(5):1550-1560.
Horn, Sarah L.; Fentiman, Ian S. 2010. "The Role of Non-Steroidal Anti-Inflammatory Drugs in the Chemoprevention of Breast Cancer." Pharmaceuticals 3, no. 5: 1550-1560.